04:24 AM EDT, 06/28/2024 (MT Newswires) -- Biogen (BIIB) said Thursday it has launched the humanized anti-soluble aggregated amyloid-beta monoclonal antibody Leqembi in China with Eisai Co. Ltd.

Leqembi received approval in January as a treatment for mild cognitive impairment due to Alzheimer's disease and mild dementia, the company said. It will first be launched in the private market in China, which is the third country to launch it after the US and Japan.

Eisai is distributing the product while also providing disease awareness and pre-screening opportunities to promote the early detection, diagnosis and treatment of Alzheimer's disease in China.

The company said that Eisai is also working to build evidence for the implementation of a definitive diagnosis of early Alzheimer's disease using blood biomarkers.

Eisai serves as the lead of Leqembi development and regulatory submissions globally, with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority, the company said.